FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2008
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Dunsire Deborah
2. Issuer Name and Ticker or Trading Symbol

MILLENNIUM PHARMACEUTICALS INC [ MLNM ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
President, CEO
(Last)          (First)          (Middle)

MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET
3. Date of Earliest Transaction (MM/DD/YYYY)

5/14/2008
(Street)

CAMBRIDGE, MA 02139
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   5/14/2008     D    688957   (1) D $25.00   0   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee stock option (right to buy)   $10.00   5/14/2008           112500      (2) 7/18/2015   Common Stock   112500   $0   0   D    
Employee stock option (right to buy)   $9.99   5/14/2008           112500      (2) 8/31/2015   Common Stock   112500   $0   0   D    
Employee stock option (right to buy)   $9.33   5/14/2008           112500      (2) 9/30/2015   Common Stock   112500   $0   0   D    
Employee stock option (right to buy)   $10.84   5/14/2008           100000      (2) 2/27/2017   Common Stock   100000   $0   0   D    
Employee stock option (right to buy)   $13.90   5/14/2008           647490      (2) 2/14/2018   Common Stock   647490   $0   0   D    

Explanation of Responses:
( 1)  Reflects shares of restricted stock that were exchanged for a cash payment of $25.00 per share in connection with the merger (the "Merger") of Mahogany Acquisition Corp. with and into Millennium Pharmaceuticals, Inc.
( 2)  This option was cancelled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price and $25.00.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Dunsire Deborah
MILLENNIUM PHARMACEUTICALS, INC.
40 LANDSDOWNE STREET
CAMBRIDGE, MA 02139
X
President, CEO

Signatures
Joel S. Goldberg, Attorney-In-Fact 5/15/2008
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Millennium Pharmaceuticals (MM) (NASDAQ:MLNM)
Historical Stock Chart
From Oct 2024 to Oct 2024 Click Here for more Millennium Pharmaceuticals (MM) Charts.
Millennium Pharmaceuticals (MM) (NASDAQ:MLNM)
Historical Stock Chart
From Oct 2023 to Oct 2024 Click Here for more Millennium Pharmaceuticals (MM) Charts.